| Name | Title | Contact Details |
|---|
Avalon Healthcare is a Tampa, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Our goal is to advance knowledge and propose crosssectoral strategies and endeavours that will improve the health and well-being of Québecers. The Institut national de santé publique du Québec (INSPQ) was created in 1998 following the adoption of its act of incorporation (RSQ, chapter I-13.1.1). Its experts come from fields as distinct as applied science, health sciences, social sciences, and humanities and work with the health and social services network to develop and pool public health knowledge and skills.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Keas is the leading Health Management platform for employers. We offer Wellbeing programs, coaching, benefits integration, and wellness incentives. Keas is dedicated to helping employers reduce health costs by reducing population health risks and encouraging smarter buying choices in healthcare. With over 70% of preventable healthcare spend wasted today, Keas leverages cutting-edge technologies in data science and behavioral economics to change behavior and slash waste, once and for all.
abeo is a nationwide medical billing and software company focused on delivering revenue-enhancing services to private practices, hospitals and surgery centers. We bridge the gap between the constant change in healthcare and your changing needs as a result. We know the healthcare landscape; we know the complexities and regulations. Our professional management services, medical billing software and anesthesia advisory services are tailored to improve the operational and financial performance for the specialty of anesthesiology. We blend our employee expertise in anesthesia with process and technology to take efficiency to the next level. Operational best practices play a key role in our ability to provide the quality of service clients receive and have come to expect from abeo. Our clients know their best interest is at the center of abeo doing their job, and doing it well.